3-HO-PCE: Difference between revisions

{{headerpanel|{{approval}}}}

'''3-Hydroxyeticyclidine''' (commonly known as '''3-HO-PCE''') is a novel synthetic [[Psychoactive class::dissociative]] substance of the [[Chemical class::arylcyclohexylamine]] chemical class. It produces potent, dose-sensitive [[dissociative]], [[hallucinogenic]] and [[euphoric]] effects when [[Routes of administration|administered]]. Unlike its close structural analog [[3-HO-PCP]], this compound is entirely novel and has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.<ref name="PCP2MXE">Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620</ref>

Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [[μ-opioid]] [[receptor]] given its structural relationship to [[3-HO-PCP]], which has been shown to display affinity for the  [[μ-opioid]] [[receptor]] in animal models.<ref name="3HOPCEsar">Kalir, A., S. Maayani, M. Rehavi, R. Elkavetz, I. Pri-Bar, O. Buchman and M. Sokolovsky, 1978, Structure activity relationship of some phencyclidine derivatives; in vivo studies in mice, European J. Med. Chem. 13, 17.</ref> Whether it produces any of its theorized [[opioid]] effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.

 

There is a complete lack of data on the pharmacological properties, metabolism, and toxicity of 3-HO-PCE, and it has an extremely brief history of human usage. It is exclusively distributed as a gray area [[research chemical]] by online vendors.<ref name="PCP2MXE /> Due to its potential habit-forming properties, and unknown toxicity profile, it is strongly recommended that one use proper [[harm reduction practices]] if choosing to use this substance.

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, which includes 3-HO-PCE.<ref> "[https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf (ACMD) Methoxetamine Report (2012)]" (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.</ref>

*'''[[Effect::Delusions]]'''

*'''[[Effect::Internal hallucinations]]''' (''[[effect::settings, sceneries, and landscapes]]''; ''[[effect::alterations in perspective]]'' and ''[[effect::scenarios and plots]]'')

Anecdotal reports which describe the effects of this compound within our [[experience index]] include:

{{#ask: [[Category:3-HO-PCE]][[Category:Experience]]|format=ul|Columns=1}}

{{Further|Research chemicals#Toxicity and harm potential}}

Tolerance to many of the effects of 3-HO-PCE are expected to develop [[Time to full tolerance::with prolonged and repeated use]]. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about [[Time to half tolerance::4 - 7 days]] for the tolerance to be reduced to half and [[Time to zero tolerance::1 - 2 weeks]] to be back at baseline (in the absence of further consumption). 3-HO-PCE presents cross-tolerance with [[Cross-tolerance::all [[dissociative]]s]], meaning that after the consumption of 3-HO-PCE, all [[dissociatives]] will have a reduced effect.

*Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.  

*The recommended dosage range should not be exceeded as high doses can trigger these effects as well.  

*Users should start with extremely low doses and work their way up as slowly as possible. [[Volumetric liquid dosing|Volumetric liquid dosing]] should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.<ref>3-HO-PCE (Tripsit) | https://wiki.tripsit.me/wiki/3-HO-PCE</ref>  

*'''Urinary frequency''' - Urinary frequency is the need to empty the bladder every few minutes.  

==Legality==

*'''United Kingdom''' - 3-HO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with a hydroxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.<ref>The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2013/239/introduction/made</ref>

===Forums===

* Morris, H., & Wallach, J. (2014). '''''From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs.''''' ''Drug Testing and Analysis'', 6(7–8), 614–632. https://doi.org/10.1002/dta.1620